|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
CN110437337B
(zh)
|
2013-02-26 |
2024-07-30 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
EP2789630A1
(en)
*
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
PL3177643T3
(pl)
|
2014-08-04 |
2019-09-30 |
F.Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
|
|
CA3001941A1
(en)
|
2015-10-30 |
2017-05-04 |
Nbe-Therapeutics Ag |
Anti-ror1 antibodies
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
MX2018008926A
(es)
|
2016-01-20 |
2019-01-10 |
Scripps Research Inst |
Composiciones de anticuerpo contra ror1 y métodos relacionados.
|
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
CN109843926B
(zh)
*
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
|
MY200973A
(en)
*
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
TWI804499B
(zh)
|
2017-06-23 |
2023-06-11 |
美商維洛斯生物公司 |
Ror1抗體免疫接合物
|
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
GB201710836D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
US20210139579A1
(en)
*
|
2017-07-20 |
2021-05-13 |
Nbe-Therapeutics Ag |
Multispecific antibody product that binds to different ror1 epitopes
|
|
KR20230008269A
(ko)
|
2017-08-07 |
2023-01-13 |
엔비이-테라퓨틱스 아게 |
생체 내 내성이 높은 항체 약물 결합체
|
|
CN107827984B
(zh)
*
|
2017-09-13 |
2021-03-16 |
张慧林 |
嵌合抗ROR1抗体Fab分子及其制备方法和应用
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
TWI829667B
(zh)
*
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CA3094318A1
(en)
|
2018-03-30 |
2019-10-03 |
Merus N.V. |
Multivalent antibody
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
KR102999339B1
(ko)
*
|
2018-04-18 |
2026-07-31 |
엑셀리시스, 인코포레이티드 |
항-ror 항체 구조체
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
KR20220024637A
(ko)
*
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
|
|
JP2022543553A
(ja)
*
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
IL300760A
(en)
*
|
2020-08-24 |
2023-04-01 |
Epimab Biotherapeutics Hk Ltd |
Anti-ROR1 antibodies and related bispecific binding proteins
|
|
EP3988568A1
(en)
*
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
WO2022146003A1
(ko)
*
|
2020-12-29 |
2022-07-07 |
삼성바이오로직스 주식회사 |
이중 또는 다중 특이적 항체
|
|
JP7858665B2
(ja)
*
|
2021-02-02 |
2026-05-14 |
ヌマブ セラピューティックス アーゲー |
Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4384218A4
(en)
*
|
2021-08-09 |
2025-11-05 |
Merck Patent Gmbh |
Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
|
|
CN120897932A
(zh)
*
|
2023-02-23 |
2025-11-04 |
阿达纳特股份有限公司 |
抗cd3抗体及其使用方法
|